Search
2024
2023
-
Mar 18, 2024
CDE Clears IND Application for Therapeutic Candidate Targeting ATTRThe first in vivo gene editing drug using lipid nanoparticle to receive clinical approval in China
Read More
-
Mar 13, 2024
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan
Read More
-
Mar 04, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPALeading the first clinical approval of an in vivo gene editing drug mediated by LNP in China
Read More
-
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing TechnologiesYolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Read More
